Floatz logo

nnc9204-0530

Metabolism and Nutrition Disorder

Novo Nordisk A/SPhase 1Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Metabolism and Nutrition Disorder cohort.

Asset / SponsorPhaseRating
Liraglutide
Anders Fink-Jensen, MD, DMSci
Phase 4A
Semaglutide
Nordsjaellands Hospital
Phase 4A
Metformin
Jinnah Sindh Medical University
Phase 4BBB
Tirzepatide
Washington University School of Medicine
Phase 4BBB
PRAVASTATIN
National Human Genome Research Institute (NHGRI)
Phase 4BBB

View all 50 →

Same molecule, other indications

nnc9204-0530 is also rated in:

obesity disorderDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →